Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer

• Sponsor: University of California, San Francisco (Other)
• Overall Status: Completed
• CT.gov ID: NCT01787331
• Collaborator: (none)
• Enrollment: 21
• Location: 1
• Arm: 1
• Actual Duration (Months): 59
• Patients Per Site Per Month: 0.4

Study Details

Study Description

Brief Summary

This phase II trial studies how well itraconazole works in treating patients with biochemically relapsed prostate cancer. Itraconazole may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Condition or Disease	Intervention/Treatment	Phase
Prostate Adenocarcinoma; Recurrent Prostate Carcinoma; Stage I Prostate Adenocarcinoma AJCC v7; Stage II Prostate Adenocarcinoma AJCC v7; Stage III Prostate Adenocarcinoma AJCC v7	Drug: Itraconazole; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study	Phase 2

Detailed Description

PRIMARY OBJECTIVES:

1. To determine whether the proportion of patients who achieve a >= 50% decline in serum prostate-specific antigen (PSA) after 12 weeks of protocol therapy with itraconazole dosed at 300 mg orally (PO) twice daily (BID) is superior to a historical control based upon the observed PSA response proportion in prior studies of non-castrating systemic therapy in men with biochemically relapsed hormone sensitive prostate cancer.

SECONDARY OBJECTIVES:

1. To determine the median time to PSA progression from the start of protocol therapy with itraconazole among men with biochemically relapsed prostate cancer.

2. To determine the median time to clinical progression measured from the start of protocol therapy with itraconazole among men with biochemically relapsed prostate cancer.

3. To determine the median metastasis-free survival measured from the start of protocol therapy in patients treated with itraconazole for biochemically relapsed prostate cancer.

4. To determine the mean percent change from baseline after 12 weeks of protocol therapy compared with pre-treatment in PSA doubling time.

5. To characterize the safety profile of itraconazole in the biochemically relapsed hormone sensitive prostate cancer population, as graded by Common Toxicity Criteria (CTCAE) version 4.03. All adverse events will be tabulated by grade according to the worst grade experienced.

6. To determine the mean steady-state itraconazole and hydroxy-itraconazole serum levels after 4 weeks of therapy with itraconazole.

Study Design

• Study Type: Interventional
• Actual Enrollment: 21 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Hedgehog Inhibition as a Non-Castrating Approach to Hormone Sensitive Prostate Cancer: A Phase II Study of Itraconazole in Biochemical Relapse
• Actual Study Start Date: Oct 29, 2013
• Actual Primary Completion Date: May 30, 2017
• Actual Study Completion Date: Sep 30, 2018

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Treatment (itraconazole) Patients receive twice/day 300mg itraconazole (oral)	Drug: Itraconazole; Given PO; Other Names: Lozanoc Oriconazole R 51,211 Sporanox ; Other: Laboratory Biomarker Analysis; Correlative studies; Other: Pharmacological Study; Correlative studies

Outcome Measures

Primary Outcome Measures

1. Number of Patients Who Achieve a Greater Than or Equal to 50% Decline in Serum Prostate Specific Antigen (PSA) [At 12 weeks after start of treatment]

   The number of patients with biochemically relapsed disease after prior definitive local therapy who achieve a ≥ 50% decline from baseline in serum PSA after 12 weeks of therapy with itraconazole, confirmed by repeat measurement at least 2 weeks later.

Secondary Outcome Measures

1. Mean Percent Change in PSA Doubling Time [Up to 12 weeks]

   The mean percent change in PSA doubling time from pre-treatment to after 12 weeks of protocol therapy

2. Median Time to PSA Progression [Up to 2 years]

   PSA progression defined as: 1. If no PSA decline is observed on therapy, PSA progression will be defined as an increase in serum PSA > 50% above the baseline PSA, and an absolute increase of > 2 ng/mL above baseline, confirmed by repeat measurement at least 2 weeks later. 2. If PSA declines on therapy, PSA progression will be defined as an increase in serum PSA > 50% above the nadir PSA on therapy, and an absolute increase > 2 ng/mL above the nadir, confirmed by repeat measurement at least 2 weeks later. The probability distribution of the time to PSA progression will be estimated using the Kaplan-Meier product limit method measured from the start of protocol therapy. The results will be summarized by the estimated median with 95% confidence intervals.

3. Median Time to Clinical Progression [Up to 2 years]

   Clinical progression will be defined as the first occurrence of either the development of metastases or initiation of non-protocol therapy, and will exclude PSA-only progression. The probability distribution of the time to clinical progression will be estimated using the Kaplan-Meier product limit method measured from the time of start of protocol therapy. The results will be summarized by the estimated median with 95% confidence intervals.

4. Median Metastasis-free Survival [Up to 2 years]

   The probability distribution of the time to first metastasis will be estimated using the Kaplan-Meier product limit method measured from the time of start of protocol therapy. The results will be summarized by the estimated median with 95% confidence intervals.

5. Percentage of Participants With Treatment-related, Adverse Changes in Vital Signs [Up to 2 years]

   All patients who receive at least one dose of study drug will be analyzed for safety endpoints. All adverse events will be graded and classified according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v. 4. Percentage of patients with grade 1 or higher, treatment-related adverse events based on the following vital sign assessments will be reported: blood pressure, pulse, respiration rate and temperature.

6. Percentage of Participants With Treatment-related, Clinical Laboratory Adverse Events [Up to 2 years]

   All patients who receive at least one dose of study drug will be analyzed for safety endpoints. All adverse events will be graded and classified according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v. 4.. Percentage of patients with grade 1 or higher, treatment-related adverse events based on the following labs will be reported: potassium, sodium, alkaline phosphatase, total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), Hematocrit, Hemoglobin, platelets, white blood cells, atypical lymphs, basophils, eosinophils, monocytes, neutrophils, blood urea nitrogen, and creatinine.

7. Mean Steady-state Trough Level of Serum Itraconazole [Up to 4 weeks]

   Descriptive statistics including the mean, standard deviation, and range of steady-state trough serum levels of itraconazole and its active metabolite hydroxy-itraconazole will be determined.

8. Mean Steady-state Trough Level of Hydroxy-itraconazole [Up to 4 weeks]

   Descriptive statistics including the mean, standard deviation, and range of steady-state trough serum levels of itraconazole and its active metabolite hydroxy-itraconazole will be determined.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Histologic confirmation of adenocarcinoma of the prostate

• Biochemically relapsed disease with a rising PSA on at least two successive measurements at least two weeks apart after prior definitive local therapy (radical prostatectomy, external beam radiation, or brachytherapy) or combination of radical prostatectomy and radiotherapy (RT) with curative intent; if the confirmatory PSA value is less than the screening PSA value, then an additional test for rising PSA will be required to documents progression

• Prior primary or salvage radiation or not a candidate for salvage radiation due to patient preference or clinical assessment based upon disease characteristics and/or patient co-morbidities

• Minimum PSA:

• If no prior androgen deprivation therapy (ADT) for biochemical relapse:

• 1.0 ng/mL if prior radical prostatectomy with or without adjuvant/salvage radiation therapy, confirmed by repeat measurement at least 2 weeks later, or

• Nadir + 2 ng/mL if prior RT alone without prior radical prostatectomy, confirmed by repeat measurement at least 2 weeks later

• If prior ADT for biochemical relapse:

• 4.0 ng/mL or > 2 ng/mL above nadir on prior cycle of ADT, whichever is higher, confirmed by repeat measurement at least 2 weeks later

• No evidence of metastatic disease on imaging by whole body bone scan (technetium-99 or sodium fluoride [Na-F] positron emission tomography [PET] bone scan) and cross-sectional imaging of the abdomen/pelvis (computed tomography [CT] or magnetic resonance imaging [MRI]) within 6 weeks of day 1 of protocol therapy

• Prior androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone (LHRH) agonist and/or antagonist allowed for either (neo)adjuvant treatment with local therapy or for biochemical relapse

• Last effective dose of LHRH agonist/antagonist ?expired? > 3 months prior to study entry; for example, a patient receiving LHRH agonist injection every 3 months would be eligible provided their last injection was > 6 months prior to day 1 of protocol therapy; a patient receiving LHRH agonist injections every 4 months will be eligible provided last injection was > 7 months prior to day 1 of protocol therapy

• Serum testosterone level:

• If no prior androgen deprivation therapy:

• A single measurement greater than 150 ng/dL within 3 months of day 1 of protocol therapy

• If prior androgen deprivation therapy (either in adjuvant or biochemical relapse setting):

• The two most recent measurements of serum testosterone prior to day 1 of protocol therapy must fulfill the following criteria:

• Both measurements are greater than 150 ng/dL

• The two measurements are spaced at least 14 days apart

• Both must be measured within 3 months of day 1 of protocol therapy

• There must not be an increase of > 50 ng/dL between these two successive measurements

• PSA doubling time (PSADT) =< 15 months, calculated based upon all serum PSA measurements obtained within 3 months prior to day 1 of protocol therapy, with a minimum of three PSA measurements spaced at least 14 days apart ; PSA values obtained when serum testosterone was known to be less than 150 ng/dL, prior to local therapy, or within three months of last dose of LHRH agonist/antagonist or antiandrogen will be excluded from the calculation of the PSADT

• Total bilirubin less than 1.5 times upper limit of normal (ULN), or less than 3 times ULN at study entry in a patient with documented Gilbert?s disease

• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels less than 1.5 times ULN at study entry

• Serum potassium greater than 3.5 mmol/L without oral supplementation

• No history of uncontrolled hypertension (blood pressure > 160/100 mm Hg despite anti-hypertensive medication)

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Estimated life expectancy greater than 5 years

• Ability to sign written informed consent

• Ability to swallow study drug whole as a capsule

• Primary prostate cancer tissue available for analysis is not required for inclusion onto this study but is strongly encouraged

• Patients who have partners of childbearing potential must be willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator and sponsor during the study and for 1 week after last study drug administration

Exclusion Criteria:

• Castrate-resistant disease, as evidenced by either:

• Rising PSA on 2 consecutive measurements at least 2 weeks apart with concurrent documented serum testosterone < 50 ng/dL at the time of PSA measurement, or

• Rising PSA on 2 consecutive measurements at least 2 weeks apart measured within 3 months after last LHRH agonist/antagonist injection

• Prior bilateral orchiectomy

• Congestive heart failure of New York Heart Association (NYHA) class III or higher severity at study entry

• History of chronic active hepatitis

• Grade 2 or higher peripheral neuropathy at the time of study entry

• Use of 5-alpha reductase antagonist (i.e. finasteride, dutasteride) or antiandrogen (i.e. flutamide, bicalutamide) within 6 weeks of day 1 of protocol therapy

• Use of systemic steroids at an equivalent dose of prednisone 5 mg/day or higher within 6 weeks of day 1 of protocol therapy

• Use of medications or herbal supplements which are known to potentially lower serum PSA within 6 weeks of day 1 of protocol therapy

• Use of other medications that may potentially interact with itraconazole within 1 week of study entry

• Use of other investigational agents within 6 weeks of day 1 of protocol therapy

• Prior pathology consistent with small cell carcinoma or prostate cancer with predominantly neuroendocrine differentiation

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of California, San Francisco	San Francisco	California	United States	94115

Sponsors and Collaborators

• University of California, San Francisco

Investigators

• Principal Investigator: Rahul Aggarwal, MD, University of California, San Francisco

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - Oct 8, 2014

More Information

Publications

None provided.

• Responsible Party: University of California, San Francisco
• ClinicalTrials.gov Identifier: NCT01787331
• Other Study ID Numbers: 125513; NCI-2013-02375
• First Posted: Feb 8, 2013
• Last Update Posted: Feb 5, 2020
• Last Verified: Jan 1, 2020

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No
• Additional relevant MeSH terms: Prostatic Neoplasms; Adenocarcinoma; Itraconazole

Study Results

Participant Flow

Arm/Group Title	Treatment (Itraconazole)
Arm/Group Description	Patients receive twice/day 300mg itraconazole (oral)
Period Title: Overall Study
STARTED	21
COMPLETED	19
NOT COMPLETED	2

Baseline Characteristics

Arm/Group Title	Treatment (Itraconazole)
Arm/Group Description	Patients receive twice/day 300mg itraconazole (oral)
Overall Participants	21
Age, Customized (participants) [Number]
40-49 Years	1 4.8%
50-59 Years	1 4.8%
60-69 Years	10 47.6%
70-79 Years	9 42.9%
Sex: Female, Male (Count of Participants)
Female	0 0%
Male	21 100%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	2 9.5%
Not Hispanic or Latino	19 90.5%
Unknown or Not Reported	0 0%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%
Asian	1 4.8%
Native Hawaiian or Other Pacific Islander	0 0%
Black or African American	0 0%
White	20 95.2%
More than one race	0 0%
Unknown or Not Reported	0 0%
Years since diagnosis of prostate cancer (years) [Mean (Full Range) ]
Mean (Full Range) [years]	7.83
Gleason Grade at Time of Diagnosis (Count of Participants)
Gleason grade ≤ 7 (low/intermediate grade)	14 66.7%
Gleason grade > 7 (high grade)	7 33.3%
Time interval from biochemical relapse to study entry (years) [Mean (Full Range) ]
Mean (Full Range) [years]	4.01
PSA doubling time at the time of study entry (months) [Mean (Full Range) ]
Mean (Full Range) [months]	5.72

Outcome Measures

1. Primary Outcome

Title	Number of Patients Who Achieve a Greater Than or Equal to 50% Decline in Serum Prostate Specific Antigen (PSA)
Description	The number of patients with biochemically relapsed disease after prior definitive local therapy who achieve a ≥ 50% decline from baseline in serum PSA after 12 weeks of therapy with itraconazole, confirmed by repeat measurement at least 2 weeks later.
Time Frame	At 12 weeks after start of treatment

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Treatment (Itraconazole)
Arm/Group Description	Patients receive twice/day 300mg itraconazole (oral)
Measure Participants	19
Count of Participants [Participants]	1 4.8%

2. Secondary Outcome

Title	Mean Percent Change in PSA Doubling Time
Description	The mean percent change in PSA doubling time from pre-treatment to after 12 weeks of protocol therapy
Time Frame	Up to 12 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Treatment (Itraconazole)
Arm/Group Description	Patients receive twice/day 300mg itraconazole (oral)
Measure Participants	19
Mean (Full Range) [Percent change in PSA doubling time]	-0.64

3. Secondary Outcome

Title	Median Time to PSA Progression
Description	PSA progression defined as: 1. If no PSA decline is observed on therapy, PSA progression will be defined as an increase in serum PSA > 50% above the baseline PSA, and an absolute increase of > 2 ng/mL above baseline, confirmed by repeat measurement at least 2 weeks later. 2. If PSA declines on therapy, PSA progression will be defined as an increase in serum PSA > 50% above the nadir PSA on therapy, and an absolute increase > 2 ng/mL above the nadir, confirmed by repeat measurement at least 2 weeks later. The probability distribution of the time to PSA progression will be estimated using the Kaplan-Meier product limit method measured from the start of protocol therapy. The results will be summarized by the estimated median with 95% confidence intervals.
Time Frame	Up to 2 years

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Treatment (Itraconazole)
Arm/Group Description	Patients receive twice/day 300mg itraconazole (oral)
Measure Participants	19
Median (Full Range) [months]	4.68

4. Secondary Outcome

Title	Median Time to Clinical Progression
Description	Clinical progression will be defined as the first occurrence of either the development of metastases or initiation of non-protocol therapy, and will exclude PSA-only progression. The probability distribution of the time to clinical progression will be estimated using the Kaplan-Meier product limit method measured from the time of start of protocol therapy. The results will be summarized by the estimated median with 95% confidence intervals.
Time Frame	Up to 2 years

Outcome Measure Data

Analysis Population Description

Only 1 patient displayed clinical progression

Arm/Group Title	Treatment (Itraconazole)
Arm/Group Description	Patients receive twice/day 300mg itraconazole (oral)
Measure Participants	1
Median (Full Range) [months]	21.7

5. Secondary Outcome

Title	Median Metastasis-free Survival
Description	The probability distribution of the time to first metastasis will be estimated using the Kaplan-Meier product limit method measured from the time of start of protocol therapy. The results will be summarized by the estimated median with 95% confidence intervals.
Time Frame	Up to 2 years

Outcome Measure Data

Analysis Population Description

Data not collected

Arm/Group Title	Treatment (Itraconazole)
Arm/Group Description	Patients receive twice/day 300mg itraconazole (oral)
Measure Participants	0

6. Secondary Outcome

Title	Percentage of Participants With Treatment-related, Adverse Changes in Vital Signs
Description	All patients who receive at least one dose of study drug will be analyzed for safety endpoints. All adverse events will be graded and classified according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v. 4. Percentage of patients with grade 1 or higher, treatment-related adverse events based on the following vital sign assessments will be reported: blood pressure, pulse, respiration rate and temperature.
Time Frame	Up to 2 years

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Treatment (Itraconazole)
Arm/Group Description	Patients receive twice/day 300mg itraconazole (oral)
Measure Participants	21
Blood Pressure	14.3 68.1%
Weight	0 0%
Pulse	0 0%
Respiration Rate	0 0%
Temperature	0 0%

7. Secondary Outcome

Title	Percentage of Participants With Treatment-related, Clinical Laboratory Adverse Events
Description	All patients who receive at least one dose of study drug will be analyzed for safety endpoints. All adverse events will be graded and classified according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v. 4.. Percentage of patients with grade 1 or higher, treatment-related adverse events based on the following labs will be reported: potassium, sodium, alkaline phosphatase, total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), Hematocrit, Hemoglobin, platelets, white blood cells, atypical lymphs, basophils, eosinophils, monocytes, neutrophils, blood urea nitrogen, and creatinine.
Time Frame	Up to 2 years

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Treatment (Itraconazole)
Arm/Group Description	Patients receive twice/day 300mg itraconazole (oral)
Measure Participants	21
Potassium	9.52 45.3%
Alanine aminotransferase	4.76 22.7%
Sodium	0 0%
Alkaline phosphatase	0 0%
Total bilirubin	0 0%
Aspartate aminotransferase	0 0%
Hematocrit	0 0%
Hemoglobin	0 0%
Platelets	0 0%
White blood cells	0 0%
Atypical lymphs	0 0%
Basophils	0 0%
Eosinophils	0 0%
Monocytes	0 0%
Neutrophils	0 0%
Blood urea nitrogen	0 0%
Creatinine	0 0%

8. Secondary Outcome

Title	Mean Steady-state Trough Level of Serum Itraconazole
Description	Descriptive statistics including the mean, standard deviation, and range of steady-state trough serum levels of itraconazole and its active metabolite hydroxy-itraconazole will be determined.
Time Frame	Up to 4 weeks

Outcome Measure Data

Analysis Population Description

No data collected

Arm/Group Title	Treatment (Itraconazole)
Arm/Group Description	Patients receive twice/day 300mg itraconazole (oral)
Measure Participants	0

9. Secondary Outcome

Title	Mean Steady-state Trough Level of Hydroxy-itraconazole
Description	Descriptive statistics including the mean, standard deviation, and range of steady-state trough serum levels of itraconazole and its active metabolite hydroxy-itraconazole will be determined.
Time Frame	Up to 4 weeks

Outcome Measure Data

Analysis Population Description

No data collected

Arm/Group Title	Treatment (Itraconazole)
Arm/Group Description	Patients receive twice/day 300mg itraconazole (oral)
Measure Participants	0

Adverse Events

Time Frame	Up to 2 years
Adverse Event Reporting Description	All patients who received at least one dose of study drug were analyzed for adverse events
Arm/Group Title	Treatment (Itraconazole)
Arm/Group Description	Patients receive twice/day 300mg itraconazole (oral)
All Cause Mortality
	Treatment (Itraconazole)
	Affected / at Risk (%)	# Events
Total	0/21 (0%)
Serious Adverse Events
	Treatment (Itraconazole)
	Affected / at Risk (%)	# Events
Total	2/21 (9.5%)
Cardiac disorders
Atrial flutter	1/21 (4.8%)
Infections and infestations
Lung infection	1/21 (4.8%)
Sepsis	1/21 (4.8%)
Investigations
Investigations - Other, specify	1/21 (4.8%)
Renal and urinary disorders
Renal and urinary disorders - Other, specify	1/21 (4.8%)
Respiratory, thoracic and mediastinal disorders
Pulmonary edema	1/21 (4.8%)
Other (Not Including Serious) Adverse Events
	Treatment (Itraconazole)
	Affected / at Risk (%)	# Events
Total	21/21 (100%)
Cardiac disorders
Atrial flutter	1/21 (4.8%)
Chest pain - cardiac	1/21 (4.8%)
Heart failure	1/21 (4.8%)
Sinus bradycardia	1/21 (4.8%)
Endocrine disorders
Adrenal insufficiency	1/21 (4.8%)
Gastrointestinal disorders
Constipation	3/21 (14.3%)
Diarrhea	3/21 (14.3%)
Nausea	3/21 (14.3%)
Abdominal pain	2/21 (9.5%)
Dry mouth	2/21 (9.5%)
Gastroesophageal reflux disease	2/21 (9.5%)
Abdominal distension	1/21 (4.8%)
Bloating	1/21 (4.8%)
Flatulence	1/21 (4.8%)
Gastrointestinal disorders - Other, specify	1/21 (4.8%)
General disorders
Edema limbs	12/21 (57.1%)
Fatigue	9/21 (42.9%)
Gait disturbance	1/21 (4.8%)
General disorders and administration site conditions - Other, specify	1/21 (4.8%)
Non-cardiac chest pain	1/21 (4.8%)
Hepatobiliary disorders
Hepatobiliary disorders - Other, specify	1/21 (4.8%)
Infections and infestations
Upper respiratory infection	5/21 (23.8%)
Rhinitis infective	1/21 (4.8%)
Urinary tract infection	1/21 (4.8%)
Investigations
Alanine aminotransferase increased	5/21 (23.8%)
Aspartate aminotransferase increased	4/21 (19%)
Blood bilirubin increased	1/21 (4.8%)
Lymphocyte count decreased	1/21 (4.8%)
Neutrophil count decreased	1/21 (4.8%)
Weight loss	1/21 (4.8%)
White blood cell decreased	1/21 (4.8%)
Metabolism and nutrition disorders
Hypokalemia	6/21 (28.6%)
Anorexia	2/21 (9.5%)
Hyperglycemia	1/21 (4.8%)
Musculoskeletal and connective tissue disorders
Pain in extremity	2/21 (9.5%)
Generalized muscle weakness	1/21 (4.8%)
Muscle weakness lower limb	1/21 (4.8%)
Nervous system disorders
Dizziness	4/21 (19%)
Headache	2/21 (9.5%)
Cognitive disturbance	1/21 (4.8%)
Dysgeusia	1/21 (4.8%)
Paresthesia	1/21 (4.8%)
Psychiatric disorders
Depression	1/21 (4.8%)
Libido decreased	1/21 (4.8%)
Renal and urinary disorders
Urinary frequency	1/21 (4.8%)
Urinary incontinence	1/21 (4.8%)
Reproductive system and breast disorders
Erectile dysfunction	1/21 (4.8%)
Respiratory, thoracic and mediastinal disorders
Dyspnea	4/21 (19%)
Cough	1/21 (4.8%)
Hoarseness	1/21 (4.8%)
Nasal congestion	1/21 (4.8%)
Sinus disorder	1/21 (4.8%)
Sore throat	1/21 (4.8%)
Wheezing	1/21 (4.8%)
Skin and subcutaneous tissue disorders
Dry skin	2/21 (9.5%)
Rash maculo-papular	2/21 (9.5%)
Nail ridging	1/21 (4.8%)
Photosensitivity	1/21 (4.8%)
Skin and subcutaneous tissue disorders - Other, specify	1/21 (4.8%)
Vascular disorders
Hypertension	6/21 (28.6%)
Hot flashes	1/21 (4.8%)
Lymphedema	1/21 (4.8%)

Limitations/Caveats

No evaluable data was collected from validated assay. Long term, metastatic disease status data was also not collected.

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.